STAT1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL160421	0.41	3/20
Suramin (SCHEMBL414636)	1.00	2/20
SCHEMBL210667	0.61	2/20
SCHEMBL212825	0.61	2/20
SCHEMBL76774	0.58	2/20
SCHEMBL236832	0.56	2/20
SCHEMBL376001	0.56	2/20
SCHEMBL211695	0.55	2/20
SCHEMBL222145	0.55	2/20
SCHEMBL211696	0.53	2/20
SCHEMBL131825	0.51	2/20
SCHEMBL17590	0.49	2/20
SCHEMBL144539	0.47	2/20
SCHEMBL130664	0.47	2/20
SCHEMBL180640	0.47	2/20
SCHEMBL456291	0.42	2/20
SCHEMBL458947	0.41	2/20
SCHEMBL63292	0.36	2/20
Ipriflavone (SCHEMBL111472)	1.00	1/20
Filgotinib (SCHEMBL253559)	1.00	1/20

Clinical trials — most relevant to STAT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial	PHASE2/PHASE3	UNKNOWN
Effect of Baricitinib Treatment on Peripheral Bone in RA	PHASE3	UNKNOWN
Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia	PHASE2	COMPLETED
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation	PHASE1/PHASE2	COMPLETED
A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer	PHASE2	RECRUITING
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma	PHASE2	COMPLETED
Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis	PHASE2	RECRUITING
Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors	PHASE2	RECRUITING
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients	PHASE1	RECRUITING
Itacitinib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis	PHASE1	COMPLETED
In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma	EARLY_PHASE1	COMPLETED
Cutaneous JAK in Vitiligo and Acne Vulgaris.	nan	UNKNOWN
Gene Expression Of Suppressor Of Cytokines in In Cutaneous Warts	nan	COMPLETED
Immune Interactions in Severe Asthma	nan	COMPLETED
Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo	nan	UNKNOWN
STAT4 in Multiple Sclerosis by PCR and Flow Cytometry	nan	COMPLETED
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma	nan	COMPLETED
Regulation of the Immune System in Response to the Treatment With Tocilizumab in Rheumatoid Arthritis Patients	nan	COMPLETED
Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients	nan	UNKNOWN
Deep Phenotyping of Cutaneous Lupus Erythematosus	nan	UNKNOWN
Clock Genes in Patients With Refractory Septic Shock (SeptiClock) - Pilot Study	nan	COMPLETED
CircularRNA-microRNA-mRNA Regulatory Axis in IVF	nan	NOT_YET_RECRUITING
Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study	nan	WITHDRAWN
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation	nan	COMPLETED
Androgenetic Alopecia and the JAK-STAT Pathway	nan	COMPLETED
A Study to Evaluate BioMarkers in Blood Samples in Subjects With Rheumatoid Arthritis	nan	COMPLETED
Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders	nan	RECRUITING
Study the Content of the HBV DNA in Liver Biopsy in the Patients Chronic Hepatitis Delta	nan	UNKNOWN
Vitamin D With Omega-3 or Metformin in Osteoarthritis	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a STAT1 binder may also engage these)

Protein	Name	Similarity
P61635	—	1.000	P61635 →
P42227	—	1.000	P42227 →
Q764M5	—	1.000	Q764M5 →
P52631	—	1.000	P52631 →
Q9PVX8	—	1.000	Q9PVX8 →
Q6DV79	—	0.999	Q6DV79 →
STAT3	Signal transducer and activator of transcription 3	0.998	landscape →
Q19S50	—	0.997	Q19S50 →
Q7ZXK3	—	0.997	Q7ZXK3 →
P42225	—	0.994	P42225 →
P42231	—	0.984	P42231 →
Q8IWV8	—	0.980	Q8IWV8 →
Q62771	—	0.980	Q62771 →
P42230	—	0.979	P42230 →
Q8BIK4	—	0.977	Q8BIK4 →
G3V7Q0	—	0.977	G3V7Q0 →
Q8IZD9	—	0.975	Q8IZD9 →
Q6PAL8	—	0.975	Q6PAL8 →
Q9BZ29	—	0.975	Q9BZ29 →
Q96JJ3	—	0.974	Q96JJ3 →
Q9TUZ1	—	0.974	Q9TUZ1 →
STAT5A	Signal transducer and activator of transcription 5A	0.974	landscape →
Q9R1D7	—	0.974	Q9R1D7 →
Q8BHL5	—	0.973	Q8BHL5 →
Q6IQ26	—	0.973	Q6IQ26 →
P52632	—	0.972	P52632 →
Q7TPD0	—	0.972	Q7TPD0 →
Q8CIQ7	—	0.971	Q8CIQ7 →
Q8BWQ6	—	0.971	Q8BWQ6 →
P23092	—	0.971	P23092 →